Comparison
Linaclotid vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
851199-59-2
396091-73-9
Molecular weight
1526.74 g/mol
1047.21 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
1
of which in humans
0
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Linaclotid and Pasireotid?
- Linaclotid is classified as "Research other", while Pasireotid is classified as "Research other". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Linaclotid or Pasireotid?
- The highest available evidence level is "Human RCT" for Linaclotid and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Linaclotid and Pasireotid in Germany and the United States?
- Germany: Linaclotid — Prescription, Pasireotid — Prescription. United States: Linaclotid — Prescription, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.